NIBEC Advances Bone Regeneration with Successful Chinese Clinical Trial and NMPA Submission

Nano Intelligence Biomedical Engineering Corporation (NIBEC), a biotech company listed on the Kosdaq, announced the successful completion of a clinical trial in China for its flagship bone regeneration product, OCS-B Collagen. The company has submitted an application for marketing approval to the National Medical Products Administration (NMPA). The trial involved 192 patients across four prominent university hospitals, including Wuhan University Hospital, Nanjing University Hospital, and Xi'an Jiaotong University Hospital. It compared OCS-B Collagen to a leading global bone graft material. Results showed that patients treated with OCS-B Collagen experienced favorable healing outcomes, with efficacy and safety comparable to the reference product. Notably, within two weeks post-operation, the incision healing rate was 96.84%, with no reports of infections or rejection. Additional assessments confirmed stable bone healing, density, and no need for re-grafting. Previously, NIBEC received NMPA approval in 2020 for its OCS-B bone graft after a clinical trial involving 280 patients across five university hospitals. The new trial further enhances NIBEC's portfolio in bone regeneration a...